To enable human leukocyte antigen (HLA) scientists and researchers to continue to advance research of histocompatibility and immunogenetics, Thermo Fisher Scientific has introduced the One Lambda™ HybriType™ HLA Plus Typing Flex kit, an next generation sequencing (NGS) hybrid capture assay featuring a probe-based design that optimizes read balance and uniformity, potentially mitigating allele dropout. 

The One Lambda HybriType assay is designed to provide flexibility in testing configuration and coverage, supporting human leukocyte antigen (HLA) Class I (4 field) and Class II (3 field) genotyping analysis across various sample types, including whole blood and buccal swabs.  

Its flexible content and extensive gene coverage may minimize ambiguity, delivering results with ≥99.8% concordance. The streamlined workflow, taking less than 5.5 hours with under 2.5 hours of hands-on time, combined with One Lambda TypeStream™ Visual NGS Software, enables rapid automated analysis.  

“We developed HybriType to enable our customers to perform deeper research into the major histocompatibility complex (MHC), a genetically rich region that plays a key role in histocompatibility and immunogenetics,” said Tina Liedtky, president, Transplant Diagnostics, Thermo Fisher Scientific. “As our knowledge of the human immune system and how the MHC may impact various conditions continues to evolve, we’re committed to providing our customers with the tools they need to further our collective understanding.”